Generex Biotech Revenue, Profits - GNBT Quarterly Income Statement

Add to My Stocks
$1.97 $0.06 (3.14%) GNBT stock closing price Sep 18, 2018 (Closing)

GNBT stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Generex Biotech stock price. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from - to - and how operating and non operating activities have impacted the GNBT stock. The Generex Biotech profit and loss statement for 2018 Q3 shows a net profit of $3.53M. Profits for last year was $-9.74M. Apart from this an investor should also check Generex Biotech assets and Generex Biotech free cash flow.

View and download details of revenue and profits for Generex Biotech for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Aug - Jul2018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q2
Generex Biotech Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
Generex Biotech Gross Profit
----------
Research & Development Expense----------
Selling General & Admin Expense----------
Income Before Depreciation Depletion Amortization-0.99M-0.16M-0.63M-0.75M-0.53M-0.21M-0.1M-0.3M-0.14M-0.15M
Depreciation Depletion Amortization----------
Non Operating Income4.57M-9.52M28.29M-11.32M-48.5M-15.44M--1.96M1.16M-
Interest Expense----------
Generex Biotech Pretax Income
3.43M-9.82M27.52M-12.39M-49.22M-15.78M--2.36M--0.04M
Provision for Income Taxes----------
MinorityInterest-0.1M-0.09M-0.11M--7.13M-0.02M----
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations3.43M-9.74M27.64M-12.73M-42.09M-15.76M--2.36M--0.05M
Extraordinary Items & Discontinued Operations----------
Generex Biotech Profit/ Loss (Net Income)
3.53M-9.74M27.64M-12.73M-42.09M-15.76M--2.36M--0.05M
Average Shares used to compute Diluted EPS2.59M1.07M2.6M1.13M1.06M-----
Average Shares used to compute Basic EPS1.07M1.07M1.07M1.13M1.06M-----
Income Before Nonrecurring Items-1.04M-0.22M-0.66M-12.73M7.45M-0.32M--0.4M--0.05M
Income from Nonrecurring Items4.57M-9.52M28.3M--49.54M-15.44M--1.97M--
Generex Biotech Earnings Per Share Basic Net
3.31-9.1225.88-11.25-39.85-17.160.000.000.000.00
Generex Biotech Earnings Per Share Diluted Net
3.31-9.1210.65-11.25-39.85-17.160.000.000.000.00
EPS Diluted Before Nonrecurring Items-0.97-0.21-0.25-11.257.05-0.350.000.000.000.00
Preferred Dividends Acc Pd----------
Dividends Common0.000.00--------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Generex Biotech stock analysis are:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2018 Q3. Our Generex Biotech revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $3.53M for Generex Biotech for 2018 Q3. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the GNBT income statement, one can check the Generex Biotech historical stock prices to check how the price has moved with time.

Generex Biotech Income Statement - Key Financial Ratios

Operating Margin
0
Net Profit Margin
0